Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Authors: Thomas Reinert, Tenna Vesterman Henriksen, Emil Christensen, Shruti Sharma, Raheleh Salari, Himanshu Sethi, Michael Knudsen, Iver Nordentoft, Hsin-Ta Wu, Antony S. Tin, Mads Heilskov Rasmussen, Søren Vang, Svetlana Shchegrova, Amanda Frydendahl Boll Johansen, Ramya Srinivasan, Zoe Assaf, Mustafa Balcioglu, Alexander Olson, Scott Dashner, Dina Hafez, Samantha Navarro, Shruti Goel, Matthew Rabinowitz, Paul Billings, Styrmir Sigurjonsson, Lars Dyrskjøt, Ryan Swenerton, Alexey Aleshin, Søren Laurberg, Anders Husted Madsen, Anne-Sofie Kannerup, Katrine Stribolt, Søren Palmelund Krag, Lene H. Iversen, Kåre Gotschalck Sunesen, Cheng-Ho Jimmy Lin, Bernhard G. Zimmermann, Claus Lindbjerg Andersen
Journal: JAMA Oncology (2019)

Novel sensitive methods for detection and monitoring of residual disease can improve postoperative risk stratification with implications for patient selection for adjuvant chemotherapy (ACT), ACT duration, intensity of radiologic surveillance, and, ultimately, outcome for patients with colorectal cancer (CRC).To investigate the association of circulating tumor DNA (ctDNA) with recurrence using longitudinal data from ultradeep sequencing of plasma cell-free DNA in patients with CRC before and after surgery, during and after ACT, and during surveillance.In this prospective, multicenter cohort study, ctDNA was quantified in the preoperative and postoperative settings of stages I to III CRC by personalized multiplex, polymerase chain reaction-based, next-generation sequencing. The study enrolled 130 patients at the surgical departments of Aarhus University Hospital, Randers Hospital, and Herning Hospital in Denmark from May 1, 2014, to January 31, 2017. Plasma samples (n = 829) were collected before surgery, postoperatively at day 30, and every third month for up to 3 years.Outcomes were ctDNA measurement, clinical recurrence, and recurrence-free survival.A total of 130 patients with stages I to III CRC (mean [SD] age, 67.9 [10.1] years; 74 [56.9%] male) were enrolled in the study; 5 patients discontinued participation, leaving 125 patients for analysis. Preoperatively, ctDNA was detectable in 108 of 122 patients (88.5%). After definitive treatment, longitudinal ctDNA analysis identified 14 of 16 relapses (87.5%). At postoperative day 30, ctDNA-positive patients were 7 times more likely to relapse than ctDNA-negative patients (hazard ratio [HR], 7.2; 95% CI, 2.7-19.0; P < .001). Similarly, shortly after ACT ctDNA-positive patients were 17 times (HR, 17.5; 95% CI, 5.4-56.5; P < .001) more likely to relapse. All 7 patients who were ctDNA positive after ACT experienced relapse. Monitoring during and after ACT indicated that 3 of the 10 ctDNA-positive patients (30.0%) were cleared by ACT. During surveillance after definitive therapy, ctDNA-positive patients were more than 40 times more likely to experience disease recurrence than ctDNA-negative patients (HR, 43.5; 95% CI, 9.8-193.5 P < .001). In all multivariate analyses, ctDNA status was independently associated with relapse after adjusting for known clinicopathologic risk factors. Serial ctDNA analyses revealed disease recurrence up to 16.5 months ahead of standard-of-care radiologic imaging (mean, 8.7 months; range, 0.8-16.5 months). Actionable mutations were identified in 81.8% of the ctDNA-positive relapse samples.Circulating tumor DNA analysis can potentially change the postoperative management of CRC by enabling risk stratification, ACT monitoring, and early relapse detection.